BioVersys AG (SWX:BIOV)
Switzerland
· Delayed Price · Currency is CHF
23.90
+0.40 (1.70%)
At close: Dec 4, 2025
BioVersys AG Cash Flow Statement
Financials in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 |
| Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| Net Income | -19.36 | -18.72 | -18.3 |
| Depreciation & Amortization | 0.28 | 0.28 | 0.27 |
| Loss (Gain) From Sale of Investments | -0.43 | -0.43 | 0.21 |
| Stock-Based Compensation | 0.46 | 1.86 | 1.72 |
| Other Operating Activities | 2.29 | 0.88 | 0.72 |
| Change in Accounts Payable | -0.99 | -2.8 | 4.8 |
| Change in Other Net Operating Assets | 1.08 | 3.36 | -1.08 |
| Operating Cash Flow | -16.67 | -15.57 | -11.66 |
| Capital Expenditures | -0.04 | -0.04 | -0.05 |
| Investment in Securities | 11 | -2 | 3.34 |
| Investing Cash Flow | 10.96 | -2.04 | 3.29 |
| Long-Term Debt Issued | - | - | 7.38 |
| Long-Term Debt Repaid | - | -0.25 | -0.25 |
| Net Debt Issued (Repaid) | -0.25 | -0.25 | 7.13 |
| Issuance of Common Stock | 76.84 | 14.71 | 0.02 |
| Other Financing Activities | -1.71 | 4.73 | -0.02 |
| Financing Cash Flow | 74.88 | 19.19 | 7.13 |
| Foreign Exchange Rate Adjustments | -0.68 | 0.66 | -0.95 |
| Net Cash Flow | 68.49 | 2.24 | -2.19 |
| Free Cash Flow | -16.71 | -15.61 | -11.7 |
| Free Cash Flow Margin | -1276.39% | -1287.06% | -1027.57% |
| Free Cash Flow Per Share | -3.75 | -4.68 | -3.92 |
| Cash Interest Paid | 0.06 | 0.08 | 0.02 |
| Levered Free Cash Flow | - | -9.46 | - |
| Unlevered Free Cash Flow | - | -8.82 | - |
| Change in Working Capital | 0.09 | 0.56 | 3.72 |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.